UNITEDHEALTH GROUP INC

UNH Healthcare & Pharma 4/10 Medium Risk
4/10

UNITEDHEALTH GROUP INC did not report standard long-term debt figures in its most recent 10-K. Approximately $6.1B (8% of maturities) is due within the next twelve months, and operating income covers interest expense 10.0x. Overall, UNH carries moderate refinancing risk (score 4/10).

Maturity Schedule

Year 1 $6.1B Year 2 $3.5B Year 3 $3.6B Year 4 $3.7B Year 5 $3.9B Beyond 5 $58.7B
Period Amount Due % of Total
Year 1 (0-12 months) $6.1B 7.7%
Year 2 (12-24 months) $3.5B 4.4%
Year 3 (24-36 months) $3.6B 4.5%
Year 4 (36-48 months) $3.7B 4.6%
Year 5 (48-60 months) $3.9B 4.9%
Beyond 5 Years $58.7B 73.9%
Total Scheduled Maturities $79.4B 100.0%

Key Metrics

Total Long-Term Debt
N/A
Near-Term (12mo)
$6.1B
Interest Coverage
10.0x
Debt/Equity
2.81
Cash Coverage
4.16x
Operating Income
$32.4B

Score Components

Component Value Weight
Near-Term Maturity Concentration 7.7% 30%
Interest Coverage Ratio 9.97x 25%
Debt-to-Equity Ratio 2.81 25%
Cash Coverage of Near-Term Debt 4.16x 20%

Related Companies

JOHNSON & JOHNSON
JNJ
1/10
Debt: $32.4B 12mo: $2.0B
PFIZER INC
PFE
5/10
Debt: $4.0B 12mo: N/A
AbbVie Inc.
ABBV
5/10
Debt: $64.5B 12mo: $6.0B
Merck & Co., Inc.
MRK
3/10
Debt: N/A 12mo: $2.6B
ELI LILLY & Co
LLY
3/10
Debt: $19.1B 12mo: $781M
BRISTOL MYERS SQUIBB CO
BMY
4/10
Debt: $49.4B 12mo: $2.0B
AMGEN INC
AMGN
5/10
Debt: $60.1B 12mo: $4.6B
GILEAD SCIENCES, INC.
GILD
4/10
Debt: $26.7B 12mo: $2.8B

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Most recent filing date: 2026-03-02. Data last fetched: 2026-03-15. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Complete.